Bibliography
- Bolger JJ, Dearnaley DP, Kirk D, et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. Semin Oncol 1993; 20(3 Suppl 2):32–3
- Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989:33(5 Suppl):57–62
- Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7):419–24 [Erratum, N Engl J Med 1989:321(20): 1420]
- Crawford ED, Kozlowski JM, Debruyne FM, et al. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 1994; 44(4):481–5 Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin North Am 1991; 18(1): 55–63
- Dijkman GA, Debruyne FM, Fernandez del Moral P, et al. A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Eur Urol 1994; 26(Suppl 1): 1–2
- Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993; 85(8):611–21 [Erratum, J Natl Cancer Inst 1994; 86(8):639–40]
- Herr HW, Kornblith AB, Ofman U.A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993; 71:1143–50
- Huggins C, Hodges CV. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293–7
- Kennealey GT, Furr BJ. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am 1991; 18(1):99–110
- The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311 (20): 1281–6
- McLeod DG, Crawford ED, Blumenstein BA, et al. Controversies in the treatment of metastatic prostate cancer. Cancer 1992; 70(1 Suppl): 324–8
- Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10(6):881–9
- Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989: 33(5 Suppl):45–52
- Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (8): 1566–72
- Schröder FH. Early versus delayed endocrine treatment in metastatic prostatic cancer. In: Murphy GP, Khoury S, eds. Therapeutic progress in urological cancers. Proceedings of an International Symposium on Therapeutic Progress in Urological Cancers, Paris, 1988. New York: Liss, 1989:253–60